Citibank put a $44 price target on abt. Suppose it's because company does not want to bust up pharma from their nutritional and diagnostic businesses. Some analysts are worried that pfe's oral tesocitinib is going to kill humira even though one of the side effedts of teso is increased ldl. Never mind that humira is used to treat 6 different autoimmune disesases - they're strictly focused on RA and forget everything else. Also when the patent expires, humira will not be easily duplicated. It is not a chemical compound. It's a biologic.
Abt is a steal at current price. Dividend is likely to be increased to $.49/qtr. per share tomorrow. Also, analysts neglect to mention abt's huge generic business - around 20% of their $40 billion annual sales which places company in the same league as teva.